GlassScriptPhysician profile
Georges S Damaa
NPI 1285839910
$949.51
in general payments reported to CMS, 2019-2025
16 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.41 · 2020: $19.87 · 2021: $24.20 · 2022: $440 · 2023: $233 · 2024: $74.07 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $440.00 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $105.09 | 2023 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $70.74 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.08 | 2020-2025 | Lifevest |
| Penumbra, INC. | $44.12 | 2025 | Penumbra System |
| Baxter Healthcare | $31.81 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| La Jolla Pharmaceutical Company | $30.68 | 2025 | Zevtera |
| Pfizer INC. | $24.20 | 2021 | |
| Terumo Medical Corporation | $23.33 | 2025 | R2p Misago, Angio-Seal, Metacross Otw |
| Janssen Pharmaceuticals, INC | $22.67 | 2023 | Spravato |
| Calliditas Therapeutics US INC. | $18.82 | 2025 | Tarpeyo |
| Kiniksa Pharmaceuticals International, Plc | $18.25 | 2024 | Arcalyst |
| Paratek Pharmaceuticals, INC. | $18.16 | 2023 | Nuzyra |
| Glaxosmithkline, LLC. | $15.62 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $13.53 | 2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georges Damaa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.